The expression level of this protein in breast cancer patients is mostly used to select patients for treatment with trastuzumab (Herceptin), a monoclonal antibody that recognizes and blocks the HER2 protein expressed on tumour cells15,16. This evidence concerns the gene ERBB2 and breast carcinoma.